Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The major active metabolite of ticagrelor, AR-C124910XX, is formed primarily by CYP3A4 and CYP3A5 in the liver. It is an equipotent reversible antagonist of the platelet P2Y12 receptor, contributing significantly to the antiplatelet effects of ticagrelor. Its formation and elimination can be influenced by other drugs and patient-specific factors, affecting overall therapeutic efficacy and safety.
Reversible antagonist of the platelet P2Y12 receptor
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ticagrelor Active Metabolite (AR-C124910XX).